Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Appili Therapeutics Inc (APLIF)

Appili Therapeutics Inc (APLIF)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 3,044
  • Shares Outstanding, K 121,266
  • Annual Sales, $ 280 K
  • Annual Income, $ -6,990 K
  • 60-Month Beta -0.30
  • Price/Sales 3.46
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade APLIF with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.04
  • Most Recent Earnings $0.00 on 02/13/24
  • Latest Earnings Date N/A
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.0212 +31.13%
on 04/01/24
0.0500 -44.40%
on 04/02/24
+0.0040 (+16.81%)
since 03/21/24
3-Month
0.0162 +71.60%
on 02/20/24
0.0500 -44.40%
on 04/02/24
+0.0053 (+23.56%)
since 01/22/24
52-Week
0.0162 +71.60%
on 02/20/24
0.0755 -63.18%
on 07/18/23
+0.0008 (+2.96%)
since 04/21/23

Most Recent Stories

More News
Appili Therapeutics to Present at the 2023 Bloom Burton & Co. Healthcare Investor Conference

Appili Therapeutics Inc. (TSX: APLI; OTCQB: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and biodefense, today announced that...

APLIF : 0.0278 (+10.76%)
Appili Therapeutics Appoints Dr. Gary Nabors as Chief Development Officer

Appili Therapeutics Inc. (TSX: APLI; OTCQB: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and biodefense, today announced that...

APLI.TO : 0.0400 (unch)
APLIF : 0.0278 (+10.76%)
Appili Therapeutics Reports Financial and Operational Results for Third Quarter of Fiscal Year 2023

Appili Therapeutics Inc. (TSX: APLI, OTCQB: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and biodefense, today announced its...

APLI.TO : 0.0400 (unch)
APLIF : 0.0278 (+10.76%)
Appili Therapeutics Appoints Dr. Carl Gelhaus and Arthur Baran to support the ATI-1701 Biodefense Vaccine Program

Appili Therapeutics Inc. (TSX: APLI; OTCQB: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and biodefense, has named Carl Gelhaus,...

APLI.TO : 0.0400 (unch)
APLIF : 0.0278 (+10.76%)
Appili Therapeutics Announces Notice of Allowance from the U.S. Patent and Trademark Office for ATI-1501 Liquid Oral Reformulation of Metronidazole

Appili Therapeutics Inc. (TSX:APLI; OTCQB: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and biodefense products, today announced...

APLI.TO : 0.0400 (unch)
APLIF : 0.0278 (+10.76%)
Appili Therapeutics ATI-1701 Biodefense Vaccine Secures ~US$14 Million of Funding from the U.S. Department of Defense in Partnership with the U.S. Air Force Academy

Appili Therapeutics Inc. (TSX: APLI; OTCQX: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and biodefense, today announced that...

APLI.TO : 0.0400 (unch)
APLIF : 0.0278 (+10.76%)
Appili Therapeutics Reports Financial and Operational Results for Second Quarter of Fiscal Year 2023

Appili Therapeutics Inc. (TSX:APLI; OTCQX: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and biodefense, today announced its...

APLI.TO : 0.0400 (unch)
APLIF : 0.0278 (+10.76%)
Appili Therapeutics Announces Results of Annual and Special Meeting of Shareholders

Appili Therapeutics Inc. (TSX: APLI; OTCQX: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and biodefense, today announced the...

APLI.TO : 0.0400 (unch)
APLIF : 0.0278 (+10.76%)
Appili Therapeutics Reports Financial and Operational Results for First Quarter of Fiscal Year 2023

Appili Therapeutics Inc. (TSX:APLI; OTCQX: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and biodefense, today announced its...

APLI.TO : 0.0400 (unch)
APLIF : 0.0278 (+10.76%)
Appili Therapeutics to Present at WorldLeish7 Conference in Cartagena, Columbia

Appili Therapeutics Inc. (TSX:APLI; OTCQX: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and biodefense, today announced that...

APLI.TO : 0.0400 (unch)
APLIF : 0.0278 (+10.76%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Weakest short term outlook on maintaining the current direction.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

Appili Therapeutics Inc. is a biopharmaceutical company. It acquires, develops and commercializes novel medicines for unmet needs in the infectious disease. The company's lead product consist ATI-2307, ATI-1501 and ATI-1701 which are in clinical stage. Appili Therapeutics Inc. is based in Halifax, Canada....

See More

Key Turning Points

3rd Resistance Point 0.0278
2nd Resistance Point 0.0278
1st Resistance Point 0.0278
Last Price 0.0278
1st Support Level 0.0278
2nd Support Level 0.0278
3rd Support Level 0.0278

See More

52-Week High 0.0755
Fibonacci 61.8% 0.0528
Fibonacci 50% 0.0458
Fibonacci 38.2% 0.0389
Last Price 0.0278
52-Week Low 0.0162

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar